Brokerages Set GALAPAGOS NV/S (GLPG) Price Target at $113.67

Shares of GALAPAGOS NV/S (NASDAQ:GLPG) have received a consensus rating of “Buy” from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $113.67.

Several equities analysts have weighed in on GLPG shares. ValuEngine raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. BidaskClub raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating in a research report on Thursday, July 19th. Zacks Investment Research raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $114.00 price target for the company in a research report on Tuesday, July 17th. Cowen reissued a “buy” rating on shares of GALAPAGOS NV/S in a research report on Thursday, May 31st. Finally, Stifel Nicolaus dropped their price target on GALAPAGOS NV/S from $120.00 to $109.00 and set a “buy” rating for the company in a research report on Friday, June 29th.

Several large investors have recently made changes to their positions in the company. Federated Investors Inc. PA grew its position in shares of GALAPAGOS NV/S by 9.3% in the second quarter. Federated Investors Inc. PA now owns 1,424,763 shares of the biotechnology company’s stock valued at $131,335,000 after purchasing an additional 121,415 shares during the period. Farallon Capital Management LLC boosted its holdings in GALAPAGOS NV/S by 6.3% in the first quarter. Farallon Capital Management LLC now owns 308,260 shares of the biotechnology company’s stock valued at $30,752,000 after acquiring an additional 18,260 shares during the last quarter. Peregrine Capital Management LLC boosted its holdings in GALAPAGOS NV/S by 5.4% in the second quarter. Peregrine Capital Management LLC now owns 107,675 shares of the biotechnology company’s stock valued at $9,925,000 after acquiring an additional 5,539 shares during the last quarter. Dorsey Wright & Associates boosted its holdings in GALAPAGOS NV/S by 9.1% in the second quarter. Dorsey Wright & Associates now owns 98,544 shares of the biotechnology company’s stock valued at $9,312,000 after acquiring an additional 8,186 shares during the last quarter. Finally, Alps Advisors Inc. boosted its holdings in GALAPAGOS NV/S by 7.7% in the second quarter. Alps Advisors Inc. now owns 73,389 shares of the biotechnology company’s stock valued at $6,765,000 after acquiring an additional 5,234 shares during the last quarter. 14.64% of the stock is owned by institutional investors and hedge funds.

NASDAQ GLPG opened at $112.27 on Friday. GALAPAGOS NV/S has a 1-year low of $84.13 and a 1-year high of $122.28.

GALAPAGOS NV/S (NASDAQ:GLPG) last released its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.41. GALAPAGOS NV/S had a negative return on equity of 13.26% and a negative net margin of 70.80%. The firm had revenue of $59.27 million during the quarter, compared to the consensus estimate of $50.58 million. equities analysts anticipate that GALAPAGOS NV/S will post -3.12 EPS for the current fiscal year.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Recommended Story: How much money do you need to begin day trading?

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply